Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CHIASMA, INC (CHMA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/05/2021 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amended and Restated Certificate of Incorporation of Chiasma",
"Amryt Successfully Completes Acquisition of Chiasma, Inc. Appoints Raj Kannan and Dr. Roni Mamluk as Non-Executive Directors Issues Ordinary Shares and Total Voting Rights"
08/03/2021 8-K Quarterly results
07/02/2021 8-K Quarterly results
06/22/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
01/19/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Executive Employment Letter, effective as of January 19, 2021, between the Company and John Doyle",
"Chiasma Announces Hiring of John Doyle as Chief Financial Officer"
01/06/2021 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Chiasma Provides Corporate Update and Previews Expected 2021 Milestones",
"Corporate presentation current as of January 6, 2021"
11/18/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor presentation furnished by Chiasma, Inc",
"Chiasma Announces Positive Topline Results from the MPOWERED ™ Phase 3 Clinical Trial Comparing MYCAPSSA ® to Long Acting Injectables for the Maintenance Treatment of Adults with Acromegaly"
11/05/2020 8-K Quarterly results
Docs: "Chiasma Reports Third Quarter 2020 Results and Provides MYCAPSSA Launch Update"
10/01/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
07/01/2020 8-K Quarterly results
06/26/2020 8-K Quarterly results
06/15/2020 8-K Submission of Matters to a Vote of Security Holders
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : June 11, 2020 Chiasma, Inc. DELAWARE 001-37500 76-0722250 140 Kendrick Street, Building C East Needham, Massachusetts 02494 928-5300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule ..."
05/07/2020 8-K Quarterly results
04/08/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : April 7, 2020 Chiasma, Inc. DELAWARE 001-37500 76-0722250 140 Kendrick Street, Building C East Needham, Massachusetts 02494 928-5300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule ...",
"Open Market Sale Agreement, by and between Chiasma, Inc. and Jefferies LLC",
"Opinion of Goodwin Procter LLP",
"Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners Needham, MA - April 8, 2020 - Chiasma, Inc. , a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its entry into a revenue interest financing agreement with HealthCare Royalty Partners for up to $75 million to support the ongoing development and planned commercial launch of its investigational octreotide capsules product candidate, trade-named MYCAPSSA ® , for the maintenance treatment of adults with acromegaly. Under the terms of the agreement, Chiasma will receive $25 million from HCR on April 14, 2020 and is entitled to receive an additional $25 million upon the U.S. Food and Drug A..."
03/16/2020 8-K Quarterly results
02/21/2020 8-K Quarterly results
01/13/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : January 13, 2020 Chiasma, Inc. DELAWARE 001-37500 76-0722250 140 Kendrick Street, Building C East Needham, Massachusetts 02494 928-5300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Ru...",
"Chiasma Announces FDA Acceptance of MYCAPSSA ® New Drug Application Resubmission"
01/10/2020 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Chiasma Provides Corporate Update and Previews 2020 Milestones",
"Corporate presentation current as of January 10, 2020"
11/05/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : November 5, 2019 Chiasma, Inc. DELAWARE 001-37500 76-0722250 460 Totten Pond Road, Suite 530 Waltham, Massachusetts 02451 928-5300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13...",
"Chiasma Reports Third Quarter 2019 Results"
08/08/2019 8-K Quarterly results
07/26/2019 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : July 25, 2019 Chiasma, Inc. DELAWARE 001-37500 76-0722250 460 Totten Pond Rd, Suite 530 Waltham, MA 02451 Registrant's telephone number, including area code 928-5300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement...",
"Underwriting Agreement, between Chiasma, Inc. and Piper Jaffray & Co. and Cantor Fitzgerald & Co",
"Opinion of Goodwin Procter LLP",
"Press release",
"Press release"
07/23/2019 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa ® for the Maintenance Treatment of Adults with Acromegaly",
"Investor Presentation furnished by Chiasma, Inc"
06/17/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : June 13, 2019 Chiasma, Inc. Delaware 001-37500 76-0722250 460 Totten Pond Road, Suite 530 Waltham, MA 02451 Registrant's telephone number, including area code 928-5300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commenceme..."
06/05/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report : May 31, 2019 Chiasma, Inc. DELAWARE 001-37500 76-0722250 460 Totten Pond Road, Suite 250 Waltham, MA 02451 Registrant's telephone number, including area code 928-5300 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencemen...",
"Employment Agreement, by and between Chiasma, Inc. and Raj Kannan",
"Amended and Restated Employment Agreement, by and between Chiasma, Inc. and Mark Fitzpatrick",
"Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa ®"
05/09/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Chiasma Reports First Quarter 2019 Results"
04/08/2019 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Slide Presentation of Chiasma, Inc. dated April 2019, furnished hereto",
"Slide Presentation of Chiasma, Inc. dated April 2019, furnished hereto"
03/29/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Underwriting Agreement, between Chiasma, Inc. and Cantor Fitzgerald & Co",
"Opinion of Goodwin Procter LLP",
"Press release",
"Press release"
03/08/2019 8-K Quarterly results
Docs: "Chiasma Reports Fourth Quarter and Year End 2018 Results"
01/03/2019 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Chiasma Previews Important Upcoming Milestones"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy